Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Dear Editor,
I consider the subject of whether to routinely eradicate Helicobacter
pylori to be important in view of its widespread occurrence and its vile
effects. In support I append a study carried out by myself for the
gastroenterologists in our Trust. My own interest in this was aroused by
the positive effect on some PD patients following eradication of Hp and
thus the study is slanted in that direction. Having said that the range of
conditions covered is staggering.
A review of Helicobacter pylori and what it may do to you
There should be great concern about the gap in time between research
findings and the practical medical use of them in the treatment of
patients. (A)
Eradication of Helicobacter pylori, a common stomach bacterium,
can greatly reduce your chances of suffering these diseases or in some
cases, reduce the symptoms already noticed:
gastritis/ dyspepsia ( 1, 4 )
gastric / duodenal ulcer ( 2, 3, 4 )
gastric cancer ( 3, 4, 5, 6,7 )
high blood pressure ( 8, 9, 10, 11 )
resolution of Syndrome X (heart and chest pain) ( 12 )
altered lipid metabolism leads to obesity, heart attack and stroke (13,
14, 15 )
iron deficiency anaemia ( 16, 17 )
abnormal blood counts (neutrophils and monocytes) ( 18, 19)
neurological damage such as Parkinson's, Alzheimer's, MS, ME, optic nerve
damage leading to blindness due to Vitamin B12 deficiency (20, 21, 22, 23
)
chronic sub-clinical vitamin deficiency of A, B6, B12, C, E
(24,25,26,27,28,29 )
skin conditions such as itchy, flaky, hard skin ( 30, 31 )
rheumatoid arthritis ( 32 )
chronic cholecystitis ( 33 )
glaucoma ( 34, 35 )
insulin resistance ( 36 )
macular degeneration leading to blindness ( 37 )
periodontal disease, tooth loss, reservoir of Hp infection in mouth (38,
39, 40)
some sexually acquired infections of nipples, vulva (41 )
These are the subjects of a large number of peer-reviewed articles in
learned journals over many years. ( reference list in numerical order is
attached)
Now it is time to do something about it.
ALL medical and gastroenterology surgical patients should be tested for
helicobacter species ( 42 ) and appropriate eradication commenced as a
matter of routine using antibiotics if required. This should be in
addition to dietary supplementation with probiotics, omega-3 oils and / or
fish oils and supplements of Vitamins A, B6, B12 and E.
Together with these there are two food additives both widely used in the
processed food industry and therefore already of proven safety for human
consumption.
One of these, 6-O-palmitoyl-l-ascorbate, (E 304), is a fat-soluble variant
of Vitamin C (ascorbic acid). It is already in use in anti-wrinkle creams,
infant formula milk, beefburgers and is used by bodybuilders to add
collagen to their intestinal and over-developed muscles. It also has the
effect of reducing the formation of new blood vessels.
It is known to eradicate Helicobacter at least as efficiently as
antibiotics, is a powerful anti-oxidant and can provide a source of
ascorbate to replace the Vitamin C lost to the Helicobacter infestation.
Ascorbate is essential for tissue repair and this lack of repair in
subclinical chronic Vitamin C deficiency accounts for many of the disease
effects listed above. It also provides a source of palmitoyl useful in the
repair process. Concentrations of this Vitamin C ester are found up to 10
times that of 'ordinary' Vitamin C in the brain. The suggested daily
intake of this powder is 250mg and it is intended to investigate the
supply of suitable tablets or capsules as soon as possible in order to
make this useful stuff available in the UK. A daily intake will cost about
10 pence. ( 43, 44, 45 )
The second additive is a modified form of fructose sold as Trehalose
(trade name Ascend™) made by Cargill Inc. It acts as a fructose
replacement and has been shown to assist with the unfolding of misfolded
proteins such as those in Lewy bodies and amyloid plaques. It is in use by
some Huntington's patients as a delaying measure and is taken in a dose of
10 –30 grams three times a day. It is available in 1350 Gram (3 pound)
packs from the USA @ about £25 per pack including postage.The suggested
daily intake is 30gm costing about 48pence ( 46, 47 )
Combination of these measures with the use of probiotics such as
Danone Fruit Layer™ yoghurt and Actimel ™ lactobacillus drink and Omega-3
oils or alternative fish or plant oils can make significant positive
differences to Parkinson's and the other diseases listed. They enable self
-repair to take place using the body's own naturally occurring stem cells
or cell repair mechanisms. Taken before hospital admission for surgery
there could be a significant reduction in recovery time and thereby
shorter SPELLS.
The use of Lactulose (prescribed by your GP) gives a further boost to
the eradication of Helicobacter and assists with the reduction of the
constipation so often a dreaded complication of Parkinsons.
By eradicating Helicobacter you will reduce the amount of antigen to
it which circulates in your blood and which has been suggested as the
cause of death of sensitive long-axon nerve cells possibly because it
stimulates platelet activity. ( 48 )
All these measures are safe and proven to be useful but it must be
remembered that your neurological condition may have taken years to
develop so expect results in months rather than days.
References re Helicobacter pylori eradication and food additives
A. The Translation of Helicobacter pylori Basic Research to Patient
Care
Peter B. Ernst, David A Peura and Sheila E. Crowe
Gastroenterology Volume 130, Issue 1, January 2006, Pages 188 - 206
1. The bidirectional communication between neurons and mast cells
within the gastrointestinal tract
Luc Van Nassauw, Dirk Adriaensen and Jean-Pierre Timmermans
Autonomic Neuroscience doi: 10.1016/j.autneu.2006.10.003
2. Critical role of an endogenous gastric peroxidase in controlling
oxidative damage in H. pylori-mediated and non-mediated gastric ulcer
Mrinalini Bhattacharjee, Samir Bhattacharjee, Arnab Gupta and Ranajit K.
Banerjee
Free Radical Biology and Medicine Volume 32, Issue 8, 15 April 2002,
pages 731 – 743
3. Helicobacter pylori infection, not gastroesophageal reflux, is
the major cause of inflammation and intestinal metaplasia of gastric
cardiac mucosa
John R. Goldblum M.D., Joel E. Richter M.D., Michael Vaezi M.D., Gary W.
Falk M.D., Thomas W. Rice M.D. and Richard M. Peek M.D.
The American Journal of Gastroenterology Volume 97, Issue 2, February
2002, pages 302 – 311
4. Serum and plasma concentration of oxidant and antioxidants in
patients of Helicobacter pylori gastritis and its correlation with gastric
cancer
Shruti S. Khanzode, Suchet D. Khanzode and Ganesh N. Dakhale
Cancer Letters Volume 195, Issue 1, 30 May 2003, pages 27 – 31
5. Carcinogenic role of tumor necrosis factor-alpha inducing
protein of Helicobacter pylori in human stomach
Suganuma, Masami; Kuzuhara, Takashi; Yamaguchi, Kensai; Fujiki, Hirota
Journal of Biochemistry and Molecular Biology Volume 39, Issue 1, January
31, 2006, Pages 1 – 8
6. Will eradication of Helicobacter pylori infection influence the risk
of gastric cancer?
Richard H. Hunt FRCP, FRCP(C), FACG
American Journal of Medicine Supplement Volume 117, Issue 5, Supplement
1, 6 September 2004, pages 86 – 91
7. Can gastric cancer be prevented by Helicobacter pylori
eradication?
Peter Malfertheiner, Professor, Lucia C Fry, Consultant and Klaus
Munkenuller, Consultant
Best Practice and Research Clinical Gastroenterology Volume 20, Issue 4,
2006, pages 709 – 719
8. Eradication of Helicobacter pylori infection improves blood
pressure values in patients affected by hypertension
Migneco, Alessio; Ojetti, Veronica; Specchia, Lucia; Franceschi,
Francesco; Candelli, Marcello; Mettimano, Marco; Montebelli, Rita; Savi,
Luigi; Gasbarrini, Giovanni
Helicobacter Volume 8, Issue 6, December 2003, pages 585 – 589
9. Prevalence of Helicobacter pylori infection in coronary artery
disease and effect of its eradication on coronary lumen reduction after
percutaneous coronary angioplasty
Kowalski M.; Konturek P.C.; Pieniazek P.; Karczewska E.; Kluczka A.; Grove
R.; Kranig W.; Nasseri R.; Thale J.; Hahn E.G.; Konturek S.J.
Digestive and Liver Disease Volume 33, Issue 3, 2001, Pages 222 – 229
10. A link between Helicobacter pylori and/or Chlamydia spp.
infections and atherosclerosis
Magdalena Chmiela, Magdalena Kowalewicz-Kulbat, Anita Miszczak, Monika
Wisniewska, Tomas Rechcinski, Katarzyna Kolodziej, Jaroslaw Kasprzak,
Torkel Wadstrom and Wieslawa Rudnicka
FEMS Immunology and Medical Microbiology Volume 36, Issue 3, 25 May 2003,
pages 187 – 192
11. Helicobacter pylori (H. pylori) infection in coronary artery
disease: influence of H. pylori eradication on coronary artery lumen after
percutaneous transluminal coronary angioplasty. The detection of H. pylori
specific DNA in human coronary atherosclerotic plaque
Kowalski, M
Journal of Physiology and Pharmacology: An Official Journal of the Polish
Physiological Society Volume 52, Issue 1, Supplement 1, August 2001,
pages 3 – 31
12. Resolution of Syndrome X after eradication of virulent CagA-
positive Helicobacter pylori
Nocente, R; Gentiloni, N; Cremonini, F; Giorgi, A; Serricchio, M;
Santoliquido, A; Gasbarrini, G; Gasbarrini, A
Southern Medical Journal Volume 93, Issue 10, October 2000, pages 1022 –
1023
13. Helicobacter pylori is associated with modified lipid profile:
impact on lipoprotein(a)
G. Chimienti, F. Russo, B. L. Lamanuzzi, M. Nardulli, C. Messa, A. Di Leo,
M. Correale, V. Gianuzzi and G. Pepe
Clinical Biochemistry Volume 36, Issue 5, July 2003, pages 359 – 365
14. Does eradication of Helicobacter pylori infection help normalise
serum lipid and CRP levels?
Kanbay M.; Gur G.; Yucel M.; Yilmaz U.; Boyacioglu S.
Digestive Diseases and Sciences Volume 50, Issue 7, 2005,
Pages 1228 – 1231
15. Association between chronic Helicobacter pylori infection and
acute ischemic stroke: Fukuoka Harasanshin Atherosclerosis Trial (FHAT)
Yasunori Sawayama, Iwao Ariyama, Maki Hamada, Shigeru Otaguro, Takao
Machi, Yuji Taira and Jun Hayashi
Atherosclerosis Volume 178, Issue 2, February 2005, Pages 303 – 309
16. A hematologist's view of unexplained iron deficiency anemia in
males: Impact of Helicobacter pylori eradication
Chaim Hershko, Mara Ianculovich and Moshe Souroujou
Blood Cells, Molecules and Diseases doi 10.1016/j.bcmd.2006.09.006
17. The clinical importance of hypochlorhydria (a consequence of
chronic Helicobacter infection): Its possible etiological role in mineral
and amino acid malabsorption, depression, and other syndromes
R. E. Cater 11
Medical Hypotheses Volume 39, Issue 4, December 1992, Pages 375 – 383
19. Effect of Helicobacter pylori eradication in patients with
chronic idiopathic thrombocytopenic purpura – A randomised controlled
trial
Suzuki T.; Matsushima M.; Masui A.; Watanabe K.-L; Takagi A.; Ogawa Y.;
Shirai T.; Mine T.
American Journal of Gastroenterology Volume 100, Issue 6, 2005, Pages
1265 – 1270
20. Alzheimer's disease and Helicobacter pylori infection: Defective
immune regulation and apoptosis as proposed common links
Jannis Kountouras, Emmanuel Gavalas, Christos Zavos, Christos
Stergiopoulos, Dimitrios Chatzopolous, Nikolaos Kapetanakis and Dimitrios
Gisakis
Medical Hypotheses Volume 68, Issue 2, 2007, Pages 378 – 388
21. Role of inflammation in gastrointestinal tract in aetiology and
pathogenesis of idiopathic parkinsonism
Clive Weller, Norman Oxlade, Sylvia M. Dobbs, R. John Dobbs, Andre
Charlett and Ingvar T. Bjarnason
FEMS Immunology and Medical Microbiology Volume 44, Issue 2, 1 May 2005,
pp 129-135
22. Link between Helicobacter pylori infection and idiopathic
parkinsonism
S.M. Dobbs, R.J. Dobbs, C. Weller and A. Charlett
Medical Hypotheses Volume 55, Issue 2, August 2000, pp93-98
23. Epidemic Optic and Peripheral Neuropathy in Cuba: A Unique
Geopolitical Public Health Problem
Thomas R. Hedges 111, MD, Michio Hirano, MD, Katherine Tucker, PHD, and
Benjamin Caballero, MD, PHD
Survey of Ophthalmology Volume 41, Number 4, January-February 1997
24. Plasma levels of antioxidant vitamins C and E are decreased in
vascular parkinsonism
George P. Paraskevas, Elizabeth Kapaki, Olga Petropolou, Maria
Anagnostouli, Vasileious Vagenas and Constantine Papageorgiou
Journal of The Neurological Sciences Volume 215, Issues 1-2, 15 November
2003, pages 51 – 55
25. Influence of gastric juice pH on the metabolism of vitamin C in
gastric mucosa and juice
Safranow K, Korzonek M, Dziedziejko V, Jacubowska K, Sulzyc-Bielicka V,
Domanski L, Ciechanowski K, Chlubek D.
Pol Merkur Lekarski, 2006 Feb; 20(116);168 –172
26. Relationship of Helicobacter pylori CagA(+) status to gastric
juice vitamin C levels
Rokkas T.; Liatsos C.; Petridou E.; Karameris A.; Ladas S.D.; Raptis S.A.
European Journal of Clinical Investigation Volume 29, Issue 1, 1999,
Pages 56-62
27. Omeprazole and dietary nitrate independently affect levels of Vitamin
C and nitrite in gastric juice
Craig Mowat, Andrew Carswell, Angela Wirz and Kenneth E. L. McColl
Gastroenterology Volume 116, Issue 4, Pages 813 – 822
28. Investigation of Helicobacter pylori ascorbic acid oxidating
activity
Lars Odum and Leif P. Andersen
FEMS Immunology and Medical Microbiology Volume 10, Issues 3-4, February
1995, Pages 289 – 294
29. Vitamin B12, demyelination, remyelination and repair in multiple
sclerosis
Ariel Miller, Maya Korem, Ronit Almog and Yanina Galboiz
Journal of the Neurological Sciences Volume 233, Issues 1-2, 15 June
2005, Pages 93 – 97
30. Tumor initiating activity of Helicobacter pylori water extract
on mouse skin carcinogenesis
Takeshi Ishikawa, Norimasa Yoshida, Harukuni Tokada, Eiichiro Ichiishi,
Masashi Kuchide, Satoshi Kokura, Yuji Naito, Shinya Toyokuni, Hoyoko
Nishino and Toshikazu Yoshikawa
Cancer Letters Volume 191, Issue 1, 28 February 2003, Pages 41 – 47
31. Therapeutic effects of the antibacterial treatment on
intractable skin diseases in Helicobacter pylori-positive patients
Mikihisa Sakurane, Matsunaka Masahiro, Koji Uede, Akiko Shiotani, Shingo
Nishioka
Department of Dermatology; Second Department of Internal Medicine,
Wakayama Medical University, Japan (Poster Display P249)
32. Eradication of Helicobacter pylori may reduce disease severity
in rheumatoid arthritis
Zentillin, P; Seriolo, B; Dulbecco, P; Caratto, E; Iiritano, E; Fasciolo,
D; Bilardi, C; Mansi, C; Testa, E; Savarino, V
Alimentary Pharmacology and Therapeutics Volume 16, Issue 7, July 2002,
Pages 1291 – 1299
33. Helicobacter pylori and other Helicobacter species in gallbladder and
liver of patients with chronic cholecystitis detected by immunological and
molecular methods
Apostolov E.; Abu Al-Soud W.; Nilsson I.; Kornilovska I.; Usenko V.;
Lyzogubov V.; Gaydar Y.; Wadstrom T.; Ljungh A.
Scandinavian Journal of Gastroenterology Volume 40, Issue 1, 2005,
Pages 96 – 102
34. Eradication of Helicobacter pylori may be beneficial in the
management of chronic open-angle glaucoma
Kountouras J.; Mylopoulos N.; Chatzopoulos D.; Zavos C.; Boura P.; Konstas
A.G.P.; Venizelos J.
Archives of Internal Medicine Volume 162, Issue 11, 10 June 2002, Pages
1237 – 1244
35. Induction of apoptosis as a proposed pathophysiological link
between glaucoma and Helicobacter pylori infection
Jannis Kountouras, Christos Zavos and Dimitrios Chatzopoulos
Medical Hypotheses Volume 62, Issue 3, March 2004, Pages 378 – 381
36. The effect of Helicobacter pylori on insulin resistance
Aydemir S.; Bayraktaroglu T.; Sert M.; Sokmen C.; Atmaca H.; Mungan G.;
Gun B.D.; Borazan A.; Ustundag Y.
Digestive Diseases and Sciences Volume 50, Issue 11, 2005, Pages 2090 –
2093
37. Association of Helicobacter pylori with central serous
chorioretinopathy: hypotheses regarding pathogenesis
Christiano Giusti
Medical Hypotheses Volume 63, Issue 3, 2004, Pages 524 – 527
38. Are dental plaque, poor oral hygiene, and periodontal disease
associated with Helicobacter pylori infection?
Anand P.S.; Nandakumar K.; Shenoy K.T.
Journal of Periodontology Volume 77, Issue 4, 2006, Pages 692 – 698
39. Expression cloning of a periodontitis-associated apoptotic effector,
cagE homologue, in Actinobacillus actinomycetemcomitans
Yen-Tung A. Teng, and Wenqui Hu
Biochemical and Biophysical Research Communications Volume 303, Issue 4,
18 April 2003, Pages 1086 – 1094
40. Persistence of Helicobacter pylori in the oral cavity after
systemic eradication therapy
Gebara E.C.E.; Faria C.M.; Pannuti C.; Chehter L.; Mayer M.P.A.; Lima
L.A.;
Journal of Clinical Periodontology Volume 33, Issue 5, May 2006,
Pages 329-333
41. Some fibrocystic breast change may be caused by sexually
transmitted H. pylori during oral nipple contact: Supporting literature
and case report of resolution after gut H. pylori eradication treatment
R.E.Kast
Medical Hypotheses doi:10.1016/j.mehy.2006.09.050 (article in press)
42. Helicobacter pylori "Test and Treat" or Endoscopy for Managing
Dyspepsia: An Individual Patient Data Meta-analysis
Alexander C. Ford, Michelle Qume, Paul Moayyedi, Nicolas L.A. Arents,
Annmarie T. Lassen, Richard F.A. Logan, Kenneth E.I. McColl, Paul Myres
and Brendan C. Delaney
Gastroenterology Volume 128, Issue 7, June 2005, Pages 1838 – 1844
43. Palmitoyl ascorbate: Selective augmentation of procollagen mRNA
expression compared with L-ascorbate in human intestinal smooth muscle
cells
Rosenblat G.; Willey A.; Zhu Y.-N.; Jonas A.; Diegelmann R.F.; Neeman I.;
Graham M.F.
Journal of Cellular Biochemistry Volume 73, Issue 3, 15 May 1999,
Pages 312 - 320
44. Diverse effects of ascorbic acid and palmitoyl ascorbate on
Helicobacter pylori survival and growth
M.Tabak, R.Armon, G. Rosenblat, E. Stermer and I. Neeman
FEMS Microbiology Letters Volume 224, Issue 2, 29 July 2003,
Pages 247-253
45. Ascorbyl Palmitate as a Carrier of Ascorbate into Neural Tissues
Mieczyslaw Pokorski, Magdalena Marczak, Aneta Dymecka, Piotr Suchocki
Journal of Biomedical Science Volume 10, Issue 2, 2003
46. Multiple Effects of Trehalose on Protein Folding In Vitro and In
Vivo
Mike A. Singer and Susan Lindquist
Molecular Cell Volume1, Issue 5, April 1998, Pages 639 – 648
47. Aggregation mechanism of polyglutamine diseases revealed using
quantum chemical calculations, fragment molecular orbital calculations,
molecular dynamics simulations, and binding free energy calculations
Koki Tsukamoto, Hideaki Shimizu, Takashi Ishida, Yutaka Akiyama and
Noboyuki Nukina
Journal of Molecular Structure: THEOCHEM Volume 778, Issues 1-3, 11
December 2006, Pages 85 – 95
48. Cholesterol synthesis inhibitors protect against platelet-
activating factor-induced neuronal damage
Clive Bate, Louis Rumbold and Alun Williams
Journal of Neuroinflammation Volume 4, Issue5, 18 January 2007
Subject for opinion poll
Dear Editor,
I consider the subject of whether to routinely eradicate Helicobacter
pylori to be important in view of its widespread occurrence and its vile
effects. In support I append a study carried out by myself for the
gastroenterologists in our Trust. My own interest in this was aroused by
the positive effect on some PD patients following eradication of Hp and
thus the study is slanted in that direction. Having said that the range of
conditions covered is staggering.
A review of Helicobacter pylori and what it may do to you
There should be great concern about the gap in time between research
findings and the practical medical use of them in the treatment of
patients. (A)
Eradication of Helicobacter pylori, a common stomach bacterium,
can greatly reduce your chances of suffering these diseases or in some
cases, reduce the symptoms already noticed:
gastritis/ dyspepsia ( 1, 4 )
gastric / duodenal ulcer ( 2, 3, 4 )
gastric cancer ( 3, 4, 5, 6,7 )
high blood pressure ( 8, 9, 10, 11 )
resolution of Syndrome X (heart and chest pain) ( 12 )
altered lipid metabolism leads to obesity, heart attack and stroke (13,
14, 15 )
iron deficiency anaemia ( 16, 17 )
abnormal blood counts (neutrophils and monocytes) ( 18, 19)
neurological damage such as Parkinson's, Alzheimer's, MS, ME, optic nerve
damage leading to blindness due to Vitamin B12 deficiency (20, 21, 22, 23
)
chronic sub-clinical vitamin deficiency of A, B6, B12, C, E
(24,25,26,27,28,29 )
skin conditions such as itchy, flaky, hard skin ( 30, 31 )
rheumatoid arthritis ( 32 )
chronic cholecystitis ( 33 )
glaucoma ( 34, 35 )
insulin resistance ( 36 )
macular degeneration leading to blindness ( 37 )
periodontal disease, tooth loss, reservoir of Hp infection in mouth (38,
39, 40)
some sexually acquired infections of nipples, vulva (41 )
These are the subjects of a large number of peer-reviewed articles in
learned journals over many years. ( reference list in numerical order is
attached)
Now it is time to do something about it.
ALL medical and gastroenterology surgical patients should be tested for
helicobacter species ( 42 ) and appropriate eradication commenced as a
matter of routine using antibiotics if required. This should be in
addition to dietary supplementation with probiotics, omega-3 oils and / or
fish oils and supplements of Vitamins A, B6, B12 and E.
Together with these there are two food additives both widely used in the
processed food industry and therefore already of proven safety for human
consumption.
One of these, 6-O-palmitoyl-l-ascorbate, (E 304), is a fat-soluble variant
of Vitamin C (ascorbic acid). It is already in use in anti-wrinkle creams,
infant formula milk, beefburgers and is used by bodybuilders to add
collagen to their intestinal and over-developed muscles. It also has the
effect of reducing the formation of new blood vessels.
It is known to eradicate Helicobacter at least as efficiently as
antibiotics, is a powerful anti-oxidant and can provide a source of
ascorbate to replace the Vitamin C lost to the Helicobacter infestation.
Ascorbate is essential for tissue repair and this lack of repair in
subclinical chronic Vitamin C deficiency accounts for many of the disease
effects listed above. It also provides a source of palmitoyl useful in the
repair process. Concentrations of this Vitamin C ester are found up to 10
times that of 'ordinary' Vitamin C in the brain. The suggested daily
intake of this powder is 250mg and it is intended to investigate the
supply of suitable tablets or capsules as soon as possible in order to
make this useful stuff available in the UK. A daily intake will cost about
10 pence. ( 43, 44, 45 )
The second additive is a modified form of fructose sold as Trehalose
(trade name Ascend™) made by Cargill Inc. It acts as a fructose
replacement and has been shown to assist with the unfolding of misfolded
proteins such as those in Lewy bodies and amyloid plaques. It is in use by
some Huntington's patients as a delaying measure and is taken in a dose of
10 –30 grams three times a day. It is available in 1350 Gram (3 pound)
packs from the USA @ about £25 per pack including postage.The suggested
daily intake is 30gm costing about 48pence ( 46, 47 )
Combination of these measures with the use of probiotics such as
Danone Fruit Layer™ yoghurt and Actimel ™ lactobacillus drink and Omega-3
oils or alternative fish or plant oils can make significant positive
differences to Parkinson's and the other diseases listed. They enable self
-repair to take place using the body's own naturally occurring stem cells
or cell repair mechanisms. Taken before hospital admission for surgery
there could be a significant reduction in recovery time and thereby
shorter SPELLS.
The use of Lactulose (prescribed by your GP) gives a further boost to
the eradication of Helicobacter and assists with the reduction of the
constipation so often a dreaded complication of Parkinsons.
By eradicating Helicobacter you will reduce the amount of antigen to
it which circulates in your blood and which has been suggested as the
cause of death of sensitive long-axon nerve cells possibly because it
stimulates platelet activity. ( 48 )
All these measures are safe and proven to be useful but it must be
remembered that your neurological condition may have taken years to
develop so expect results in months rather than days.
References re Helicobacter pylori eradication and food additives
A. The Translation of Helicobacter pylori Basic Research to Patient
Care
Peter B. Ernst, David A Peura and Sheila E. Crowe
Gastroenterology Volume 130, Issue 1, January 2006, Pages 188 - 206
1. The bidirectional communication between neurons and mast cells
within the gastrointestinal tract
Luc Van Nassauw, Dirk Adriaensen and Jean-Pierre Timmermans
Autonomic Neuroscience doi: 10.1016/j.autneu.2006.10.003
2. Critical role of an endogenous gastric peroxidase in controlling
oxidative damage in H. pylori-mediated and non-mediated gastric ulcer
Mrinalini Bhattacharjee, Samir Bhattacharjee, Arnab Gupta and Ranajit K.
Banerjee
Free Radical Biology and Medicine Volume 32, Issue 8, 15 April 2002,
pages 731 – 743
3. Helicobacter pylori infection, not gastroesophageal reflux, is
the major cause of inflammation and intestinal metaplasia of gastric
cardiac mucosa
John R. Goldblum M.D., Joel E. Richter M.D., Michael Vaezi M.D., Gary W.
Falk M.D., Thomas W. Rice M.D. and Richard M. Peek M.D.
The American Journal of Gastroenterology Volume 97, Issue 2, February
2002, pages 302 – 311
4. Serum and plasma concentration of oxidant and antioxidants in
patients of Helicobacter pylori gastritis and its correlation with gastric
cancer
Shruti S. Khanzode, Suchet D. Khanzode and Ganesh N. Dakhale
Cancer Letters Volume 195, Issue 1, 30 May 2003, pages 27 – 31
5. Carcinogenic role of tumor necrosis factor-alpha inducing
protein of Helicobacter pylori in human stomach
Suganuma, Masami; Kuzuhara, Takashi; Yamaguchi, Kensai; Fujiki, Hirota
Journal of Biochemistry and Molecular Biology Volume 39, Issue 1, January
31, 2006, Pages 1 – 8
6. Will eradication of Helicobacter pylori infection influence the risk
of gastric cancer?
Richard H. Hunt FRCP, FRCP(C), FACG
American Journal of Medicine Supplement Volume 117, Issue 5, Supplement
1, 6 September 2004, pages 86 – 91
7. Can gastric cancer be prevented by Helicobacter pylori
eradication?
Peter Malfertheiner, Professor, Lucia C Fry, Consultant and Klaus
Munkenuller, Consultant
Best Practice and Research Clinical Gastroenterology Volume 20, Issue 4,
2006, pages 709 – 719
8. Eradication of Helicobacter pylori infection improves blood
pressure values in patients affected by hypertension
Migneco, Alessio; Ojetti, Veronica; Specchia, Lucia; Franceschi,
Francesco; Candelli, Marcello; Mettimano, Marco; Montebelli, Rita; Savi,
Luigi; Gasbarrini, Giovanni
Helicobacter Volume 8, Issue 6, December 2003, pages 585 – 589
9. Prevalence of Helicobacter pylori infection in coronary artery
disease and effect of its eradication on coronary lumen reduction after
percutaneous coronary angioplasty
Kowalski M.; Konturek P.C.; Pieniazek P.; Karczewska E.; Kluczka A.; Grove
R.; Kranig W.; Nasseri R.; Thale J.; Hahn E.G.; Konturek S.J.
Digestive and Liver Disease Volume 33, Issue 3, 2001, Pages 222 – 229
10. A link between Helicobacter pylori and/or Chlamydia spp.
infections and atherosclerosis
Magdalena Chmiela, Magdalena Kowalewicz-Kulbat, Anita Miszczak, Monika
Wisniewska, Tomas Rechcinski, Katarzyna Kolodziej, Jaroslaw Kasprzak,
Torkel Wadstrom and Wieslawa Rudnicka
FEMS Immunology and Medical Microbiology Volume 36, Issue 3, 25 May 2003,
pages 187 – 192
11. Helicobacter pylori (H. pylori) infection in coronary artery
disease: influence of H. pylori eradication on coronary artery lumen after
percutaneous transluminal coronary angioplasty. The detection of H. pylori
specific DNA in human coronary atherosclerotic plaque
Kowalski, M
Journal of Physiology and Pharmacology: An Official Journal of the Polish
Physiological Society Volume 52, Issue 1, Supplement 1, August 2001,
pages 3 – 31
12. Resolution of Syndrome X after eradication of virulent CagA-
positive Helicobacter pylori
Nocente, R; Gentiloni, N; Cremonini, F; Giorgi, A; Serricchio, M;
Santoliquido, A; Gasbarrini, G; Gasbarrini, A
Southern Medical Journal Volume 93, Issue 10, October 2000, pages 1022 –
1023
13. Helicobacter pylori is associated with modified lipid profile:
impact on lipoprotein(a)
G. Chimienti, F. Russo, B. L. Lamanuzzi, M. Nardulli, C. Messa, A. Di Leo,
M. Correale, V. Gianuzzi and G. Pepe
Clinical Biochemistry Volume 36, Issue 5, July 2003, pages 359 – 365
14. Does eradication of Helicobacter pylori infection help normalise
serum lipid and CRP levels?
Kanbay M.; Gur G.; Yucel M.; Yilmaz U.; Boyacioglu S.
Digestive Diseases and Sciences Volume 50, Issue 7, 2005,
Pages 1228 – 1231
15. Association between chronic Helicobacter pylori infection and
acute ischemic stroke: Fukuoka Harasanshin Atherosclerosis Trial (FHAT)
Yasunori Sawayama, Iwao Ariyama, Maki Hamada, Shigeru Otaguro, Takao
Machi, Yuji Taira and Jun Hayashi
Atherosclerosis Volume 178, Issue 2, February 2005, Pages 303 – 309
16. A hematologist's view of unexplained iron deficiency anemia in
males: Impact of Helicobacter pylori eradication
Chaim Hershko, Mara Ianculovich and Moshe Souroujou
Blood Cells, Molecules and Diseases doi 10.1016/j.bcmd.2006.09.006
17. The clinical importance of hypochlorhydria (a consequence of
chronic Helicobacter infection): Its possible etiological role in mineral
and amino acid malabsorption, depression, and other syndromes
R. E. Cater 11
Medical Hypotheses Volume 39, Issue 4, December 1992, Pages 375 – 383
18. Helicobacter pylori eradication decreases blood neutrophil and
monocyte counts
Kondo Y.; Joh T.; Sasaki M.; Oshima T.; Itoh K.; Tanida S.; Kataoka H.;
Ohara H.; Nomura T.; Itoh M.
Alimentary Pharmacology and Therapeutics, Supplement Volume 20, Issue1,
2004, pages 74 – 79
19. Effect of Helicobacter pylori eradication in patients with
chronic idiopathic thrombocytopenic purpura – A randomised controlled
trial
Suzuki T.; Matsushima M.; Masui A.; Watanabe K.-L; Takagi A.; Ogawa Y.;
Shirai T.; Mine T.
American Journal of Gastroenterology Volume 100, Issue 6, 2005, Pages
1265 – 1270
20. Alzheimer's disease and Helicobacter pylori infection: Defective
immune regulation and apoptosis as proposed common links
Jannis Kountouras, Emmanuel Gavalas, Christos Zavos, Christos
Stergiopoulos, Dimitrios Chatzopolous, Nikolaos Kapetanakis and Dimitrios
Gisakis
Medical Hypotheses Volume 68, Issue 2, 2007, Pages 378 – 388
21. Role of inflammation in gastrointestinal tract in aetiology and
pathogenesis of idiopathic parkinsonism
Clive Weller, Norman Oxlade, Sylvia M. Dobbs, R. John Dobbs, Andre
Charlett and Ingvar T. Bjarnason
FEMS Immunology and Medical Microbiology Volume 44, Issue 2, 1 May 2005,
pp 129-135
22. Link between Helicobacter pylori infection and idiopathic
parkinsonism
S.M. Dobbs, R.J. Dobbs, C. Weller and A. Charlett
Medical Hypotheses Volume 55, Issue 2, August 2000, pp93-98
23. Epidemic Optic and Peripheral Neuropathy in Cuba: A Unique
Geopolitical Public Health Problem
Thomas R. Hedges 111, MD, Michio Hirano, MD, Katherine Tucker, PHD, and
Benjamin Caballero, MD, PHD
Survey of Ophthalmology Volume 41, Number 4, January-February 1997
24. Plasma levels of antioxidant vitamins C and E are decreased in
vascular parkinsonism
George P. Paraskevas, Elizabeth Kapaki, Olga Petropolou, Maria
Anagnostouli, Vasileious Vagenas and Constantine Papageorgiou
Journal of The Neurological Sciences Volume 215, Issues 1-2, 15 November
2003, pages 51 – 55
25. Influence of gastric juice pH on the metabolism of vitamin C in
gastric mucosa and juice
Safranow K, Korzonek M, Dziedziejko V, Jacubowska K, Sulzyc-Bielicka V,
Domanski L, Ciechanowski K, Chlubek D.
Pol Merkur Lekarski, 2006 Feb; 20(116);168 –172
26. Relationship of Helicobacter pylori CagA(+) status to gastric
juice vitamin C levels
Rokkas T.; Liatsos C.; Petridou E.; Karameris A.; Ladas S.D.; Raptis S.A.
European Journal of Clinical Investigation Volume 29, Issue 1, 1999,
Pages 56-62
27. Omeprazole and dietary nitrate independently affect levels of Vitamin
C and nitrite in gastric juice
Craig Mowat, Andrew Carswell, Angela Wirz and Kenneth E. L. McColl
Gastroenterology Volume 116, Issue 4, Pages 813 – 822
28. Investigation of Helicobacter pylori ascorbic acid oxidating
activity
Lars Odum and Leif P. Andersen
FEMS Immunology and Medical Microbiology Volume 10, Issues 3-4, February
1995, Pages 289 – 294
29. Vitamin B12, demyelination, remyelination and repair in multiple
sclerosis
Ariel Miller, Maya Korem, Ronit Almog and Yanina Galboiz
Journal of the Neurological Sciences Volume 233, Issues 1-2, 15 June
2005, Pages 93 – 97
30. Tumor initiating activity of Helicobacter pylori water extract
on mouse skin carcinogenesis
Takeshi Ishikawa, Norimasa Yoshida, Harukuni Tokada, Eiichiro Ichiishi,
Masashi Kuchide, Satoshi Kokura, Yuji Naito, Shinya Toyokuni, Hoyoko
Nishino and Toshikazu Yoshikawa
Cancer Letters Volume 191, Issue 1, 28 February 2003, Pages 41 – 47
31. Therapeutic effects of the antibacterial treatment on
intractable skin diseases in Helicobacter pylori-positive patients
Mikihisa Sakurane, Matsunaka Masahiro, Koji Uede, Akiko Shiotani, Shingo
Nishioka
Department of Dermatology; Second Department of Internal Medicine,
Wakayama Medical University, Japan (Poster Display P249)
32. Eradication of Helicobacter pylori may reduce disease severity
in rheumatoid arthritis
Zentillin, P; Seriolo, B; Dulbecco, P; Caratto, E; Iiritano, E; Fasciolo,
D; Bilardi, C; Mansi, C; Testa, E; Savarino, V
Alimentary Pharmacology and Therapeutics Volume 16, Issue 7, July 2002,
Pages 1291 – 1299
33. Helicobacter pylori and other Helicobacter species in gallbladder and
liver of patients with chronic cholecystitis detected by immunological and
molecular methods
Apostolov E.; Abu Al-Soud W.; Nilsson I.; Kornilovska I.; Usenko V.;
Lyzogubov V.; Gaydar Y.; Wadstrom T.; Ljungh A.
Scandinavian Journal of Gastroenterology Volume 40, Issue 1, 2005,
Pages 96 – 102
34. Eradication of Helicobacter pylori may be beneficial in the
management of chronic open-angle glaucoma
Kountouras J.; Mylopoulos N.; Chatzopoulos D.; Zavos C.; Boura P.; Konstas
A.G.P.; Venizelos J.
Archives of Internal Medicine Volume 162, Issue 11, 10 June 2002, Pages
1237 – 1244
35. Induction of apoptosis as a proposed pathophysiological link
between glaucoma and Helicobacter pylori infection
Jannis Kountouras, Christos Zavos and Dimitrios Chatzopoulos
Medical Hypotheses Volume 62, Issue 3, March 2004, Pages 378 – 381
36. The effect of Helicobacter pylori on insulin resistance
Aydemir S.; Bayraktaroglu T.; Sert M.; Sokmen C.; Atmaca H.; Mungan G.;
Gun B.D.; Borazan A.; Ustundag Y.
Digestive Diseases and Sciences Volume 50, Issue 11, 2005, Pages 2090 –
2093
37. Association of Helicobacter pylori with central serous
chorioretinopathy: hypotheses regarding pathogenesis
Christiano Giusti
Medical Hypotheses Volume 63, Issue 3, 2004, Pages 524 – 527
38. Are dental plaque, poor oral hygiene, and periodontal disease
associated with Helicobacter pylori infection?
Anand P.S.; Nandakumar K.; Shenoy K.T.
Journal of Periodontology Volume 77, Issue 4, 2006, Pages 692 – 698
39. Expression cloning of a periodontitis-associated apoptotic effector,
cagE homologue, in Actinobacillus actinomycetemcomitans
Yen-Tung A. Teng, and Wenqui Hu
Biochemical and Biophysical Research Communications Volume 303, Issue 4,
18 April 2003, Pages 1086 – 1094
40. Persistence of Helicobacter pylori in the oral cavity after
systemic eradication therapy
Gebara E.C.E.; Faria C.M.; Pannuti C.; Chehter L.; Mayer M.P.A.; Lima
L.A.;
Journal of Clinical Periodontology Volume 33, Issue 5, May 2006,
Pages 329-333
41. Some fibrocystic breast change may be caused by sexually
transmitted H. pylori during oral nipple contact: Supporting literature
and case report of resolution after gut H. pylori eradication treatment
R.E.Kast
Medical Hypotheses doi:10.1016/j.mehy.2006.09.050 (article in press)
42. Helicobacter pylori "Test and Treat" or Endoscopy for Managing
Dyspepsia: An Individual Patient Data Meta-analysis
Alexander C. Ford, Michelle Qume, Paul Moayyedi, Nicolas L.A. Arents,
Annmarie T. Lassen, Richard F.A. Logan, Kenneth E.I. McColl, Paul Myres
and Brendan C. Delaney
Gastroenterology Volume 128, Issue 7, June 2005, Pages 1838 – 1844
43. Palmitoyl ascorbate: Selective augmentation of procollagen mRNA
expression compared with L-ascorbate in human intestinal smooth muscle
cells
Rosenblat G.; Willey A.; Zhu Y.-N.; Jonas A.; Diegelmann R.F.; Neeman I.;
Graham M.F.
Journal of Cellular Biochemistry Volume 73, Issue 3, 15 May 1999,
Pages 312 - 320
44. Diverse effects of ascorbic acid and palmitoyl ascorbate on
Helicobacter pylori survival and growth
M.Tabak, R.Armon, G. Rosenblat, E. Stermer and I. Neeman
FEMS Microbiology Letters Volume 224, Issue 2, 29 July 2003,
Pages 247-253
45. Ascorbyl Palmitate as a Carrier of Ascorbate into Neural Tissues
Mieczyslaw Pokorski, Magdalena Marczak, Aneta Dymecka, Piotr Suchocki
Journal of Biomedical Science Volume 10, Issue 2, 2003
46. Multiple Effects of Trehalose on Protein Folding In Vitro and In
Vivo
Mike A. Singer and Susan Lindquist
Molecular Cell Volume1, Issue 5, April 1998, Pages 639 – 648
47. Aggregation mechanism of polyglutamine diseases revealed using
quantum chemical calculations, fragment molecular orbital calculations,
molecular dynamics simulations, and binding free energy calculations
Koki Tsukamoto, Hideaki Shimizu, Takashi Ishida, Yutaka Akiyama and
Noboyuki Nukina
Journal of Molecular Structure: THEOCHEM Volume 778, Issues 1-3, 11
December 2006, Pages 85 – 95
48. Cholesterol synthesis inhibitors protect against platelet-
activating factor-induced neuronal damage
Clive Bate, Louis Rumbold and Alun Williams
Journal of Neuroinflammation Volume 4, Issue5, 18 January 2007
Competing interests:
None declared
Competing interests: No competing interests